Correction: The Cytokine Release Inhibitory Drug CRID3 Targets ASC Oligomerisation in the NLRP3 and AIM2 Inflammasomes
Rebecca C. Coll(Queen's University Belfast), Luke O'neill(Trinity College Dublin)
Cited by 0
Related Papers
Metabolic reprogramming in macrophages and dendritic cells in innate immunity
|Cell Research|2015|1.8k
MCC950 directly targets the NLRP3 ATP-hydrolysis motif for inflammasome inhibition
|Nature Chemical Biology|2019|975
Targeting Toll-like receptors: emerging therapeutics?
|Nature Reviews Drug Discovery|2010|883
Trained immunity, tolerance, priming and differentiation: distinct immunological processes
|Nature Immunology|2020|591
The Immunomodulatory Metabolite Itaconate Modifies NLRP3 and Inhibits Inflammasome Activation
|Cell Metabolism|2020|571